Oncopeptides AB ONCO
OMXSTO · Sweden · Health Technology
SEK 2.16-0.02 (-1.10%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Strong revenue growth and disciplined cost management position the company for positive cash flow in 2027, despite regional market challenges.
Oncopeptides AB (FRA:OND) reports impressive sales growth and strategic advancements, despite facing regional hurdles and regulatory delays.
Despite challenges in key markets, Oncopeptides AB (STU:OND) reports significant sales growth and outlines strategic initiatives to enhance its pipeline and market reach.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.